Abstract: Provided herein are controlled release gastro retentive dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile.

Abstract: Provided herein are controlled release multiparticulate dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile.

Abstract: Disclosed are various approaches for extending a single sign-on (SSO) session to multiple devices. If a device is enrolled as a managed device with a management service, a SSO session can be extended to the device if the user has previously authenticated with an identity provider from another device. The user is authenticated on the second device using a user-and-device token issued by the management service with which the device is enrolled as a managed device.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Oral dosage forms comprising eltrombopag choline, processes for preparation thereof and methods of use thereof are disclosed. The compositions disclosed exhibit enhanced bioavailability and reduced food effect compared to commercially available formulations of eltrombopag.

Abstract: Disclosed are various approaches for extending a single sign-on (SSO) session to multiple devices. If a device is enrolled as a managed device with a management service, a SSO session can be extended to the device if the user has previously authenticated with an identity provider from another device. The user is authenticated on the second device using a user-and-device token issued by the management service with which the device is enrolled as a managed device.

Abstract: Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Abstract: Disclosed are various approaches for extending a single sign-on (SSO) session to multiple devices. If a device is enrolled as a managed device with a management service, a SSO session can be extended to the device if the user has previously authenticated with an identity provider from another device. The user is authenticated on the second device using a user-and-device token issued by the management service with which the device is enrolled as a managed device.

Abstract: Disclosed are various approaches for extending a single sign-on (SSO) session to multiple devices. If a device is enrolled as a managed device with a management service, a SSO session can be extended to the device if the user has previously authenticated with an identity provider from another device. The user is authenticated on the second device using a user-and-device token issued by the management service with which the device is enrolled as a managed device.

Abstract: Disclosed are gastroretentive, sustained-release tablet formulations comprising an active agent, such as pregabalin or a pharmaceutically acceptable form thereof, crospovidone, and a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer.

Abstract: A method for information management comprises intercepting an output from an application; distributing packets according to a routing scheme, wherein the packets are associated with the output, and wherein distributing the packets may occur when the application is associated with a first operating system, and may also occur when the application is associated with a second operating system; and storing the packets.

Abstract: Information management is disclosed. A file output from an application to an operating system is intercepted before the file output arrives at the operating system. The file output is directed towards protected data. The intercepted file output is analyzed to determine whether a predetermined type of version of the protected data has been created. In the event it is determined that the predetermined type of version of the protected data has been created at least in part because the analyzed intercepted file output includes a modification to the protected data, the protected data automatically backed up, including by storing at least a portion of the file output as a backup version of the protected data. In the event it is determined that the predetermined type of version of the protected data has not been created, the protected data is not backed up.

Abstract: A method for information management comprises monitoring output from an application to an operating system, wherein the output is monitored substantially continuously; determining if a policy applies to data associated with the output; and executing the policy if the policy applies.

Abstract: Information management is disclosed. A file output from an application to an operating system is intercepted before the file output arrives at the operating system. The file output is directed towards protected data. The intercepted file output is analyzed to determine whether a predetermined type of version of the protected data has been created. In the event it is determined that the predetermined type of version of the protected data has been created at least in part because the analyzed intercepted file output includes a modification to the protected data, the protected data automatically backed up, including by storing at least a portion of the file output as a backup version of the protected data. In the event it is determined that the predetermined type of version of the protected data has not been created, the protected data is not backed up.

Abstract: In one embodiment, a method for information management comprises monitoring output from an application, wherein the output is monitored substantially continuously; determining if the output is associated with a predetermined type of version; and saving data associated with the output if the output is associated with the predetermined type of version.

Abstract: An indication to allocate storage is received, where the storage is to be used to store previous version data associated with a protected data set. One or more storage groups are allocated of at least a prescribed allocation group size and comprising a set of physically contiguous storage locations.

Abstract: An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.

Abstract: An extended release pharmaceutical composition of Levetiracetam with once a day dosage regime and the process of preparing it. The extended release tablet of Levetiracetam is with the core comprising of Levetiracetam and water dispersible rate controlling polymer, and the tablet core is optionally functional coated comprising a combination of water non-dispersible and/or water dispersible polymer. It provides extended therapeutically effective plasma levels over a twenty four hour period with diminished incidences of neuropsychiatric adverse events by eliminating the troughs and peaks of drug concentration in a patients blood plasma, which comprises administering orally to a patient in need thereof, an extended release tablet that provides a peak blood plasma level of Levetiracetam in from about eight to about Sixteen hours. The core is prepared by Wet granulation, Dry granulation or Direct compression and optionally the tablet core is coated either in an coating pan or in and Fluidized bed system.